Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
IPO Year:
Exchange: NYSE
Website: smith-nephew.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/25/2025 | Buy → Hold | HSBC Securities | |
3/12/2025 | Buy → Neutral | UBS | |
11/6/2024 | Buy → Hold | Berenberg | |
11/1/2024 | Buy → Hold | Deutsche Bank | |
7/24/2024 | Buy | Deutsche Bank | |
6/5/2024 | Neutral → Buy | UBS | |
11/28/2023 | Underweight → Equal Weight | Barclays | |
11/3/2023 | Neutral → Overweight | JP Morgan | |
10/31/2023 | Hold → Buy | HSBC Securities | |
10/13/2023 | Hold | Stifel |
HSBC Securities downgraded Smith & Nephew from Buy to Hold
UBS downgraded Smith & Nephew from Buy to Neutral
Berenberg downgraded Smith & Nephew from Buy to Hold
Deutsche Bank downgraded Smith & Nephew from Buy to Hold
Deutsche Bank initiated coverage of Smith & Nephew with a rating of Buy
UBS upgraded Smith & Nephew from Neutral to Buy
Barclays upgraded Smith & Nephew from Underweight to Equal Weight
JP Morgan upgraded Smith & Nephew from Neutral to Overweight
HSBC Securities upgraded Smith & Nephew from Hold to Buy
Stifel initiated coverage of Smith & Nephew with a rating of Hold